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Flavokawain  A (FKA),  a major  chalcone  in  the  Kava  plant,  has  recently  demonstrated  promis-
ing anti-cancer  activities.  A systematic  evaluation  of  FKA’s  safety  proﬁle  has  not  been
reported  before.  In this  study,  male  FVB/N  mice  were  fed  with  an  AIN-76A  diet  or AIN-
76A  diet  supplemented  with  0.6%  (6 g/kg  food)  FKA  or  0.6% commercial  kava  root  extract
(KRE)  for  three  weeks.  Dietary  feeding  of FKA  did not  affect  food  consumption  and  body
weight.  Histopathological  examination  of liver,  kidney,  colon,  lung,  heart,  spleen,  and  thy-
mus revealed  no  signs  of FKA-induced  toxicity.  Biochemical  serum  analysis  and  histological
examination  conﬁrmed  normal  organ  function  in  FKA-treated  mice.  The  cytotoxicity  proﬁle
showed FKA  had  minimal  side  effects  on bone  marrow  and  small  intestinal  epithelial  cells
compared  with  Adriamycin.  In addition,  oral feeding  of FKA  increased  activities  of  both
glutathione  S-transferase  and  quinone  reductase  in the  liver, lung,  prostate  and bladder
tissues  of mice.  In comparison,  dietary  feeding  of 0.6% KRE  increased  liver/body  weight
ratio  and decreased  spleen,  thymus,  and  testis/body  weight  ratios,  as well  as  induced
nodular  proliferation  in  liver  tissues.  Therefore,  dietary  feeding  FKA  showed  no adverse
effects  on  major  organ  function  and  homeostasis  in  mice,  suggesting  the  potential  of  FKA
for chemoprevention  study  of  human  cancers.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe CC  B
1. BackgroundAccording to the GLOBOCAN08 [1], Cancer Incidence
and Mortality Worldwide 2008 report, age-standardized
incidences of cancer, including lung and bladder
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cancers, in three kava drinking paciﬁc countries (Fiji,
Vanutu and Samoa) were markedly lower than those
in  their neighbor countries, such as Australia and New
Zealand, despite of the higher percentages of smokers in
their  populations (up to 58.3% of man  in Samoa smoke).
Steiner [2] reported that the age-standardized cancer
incidence for the three highest kava-drinking countries
(Vanuatu, Fiji, and Western Samoa) was  one fourth or one
third  that of non-kava-drinking countries, such as New
Zealand and the United States, and non-kava-drinking
Polynesians (Maoris). Uniquely, in these three kava
is is an open access article under the CC BY-NC-ND license
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rinking countries more men  drink kava and smoke than
o  women, yet there is a lower incidence of cancer for
en  than for women. These reports have prompted us
nd  others [3–9] to investigate the potential beneﬁts of
ava  root extracts and its active components for cancer
revention.
Kava (Piper methysticum Forst) is a perennial plant
ndigenous to the South Paciﬁc Islands. A water infusion
f  Kava roots has been safely used as a traditional bev-
rage with relaxant effects on a daily basis in the Paciﬁc
slands for thousands of years [10]. Recently, we and oth-
rs  have demonstrated that kava root extracts have potent
nti-cancer and anti-carcinogenic activity in animal exper-
ments  [3–5,11,12]. However, there were rare reported
ases of hepatotoxicity (0.25/1,000,000) linked to the use
f  commercial kava root extracts (from organic solvent
xtraction) in Western countries, which is lower than the
ate  of hepatic adverse effects (0.90–2.12 cases/1,000,000)
or many daily-use drugs (e.g. anxiolytic benzodiazepines)
13]. To address the concern for kava hepatotoxicity and
o  develop a well-characterized chemopreventive candi-
ate  with minimized adverse side effects, we and others
ave  focused on identifying non-toxic and pure kava com-
onents  for cancer prevention [3–9,14–16]. In our initial
creening for anti-cancer agents from kava extracts, we
ound  that ﬂavokawains (ﬂavokawain A, B and C) were the
ost  potent agents among about 40 chemicals from kava
xtracts  to induce apoptosis in cancer cell lines [9].
Several kava components, including kavalactones,
ipermethystine, ﬂavokawain B and contaminant hepa-
otoxins, have been claimed by different studies to be
esponsible for the reported kava hepatotoxicity [17–20].
owever, convincing evidence regarding kava hepato-
oxicity is still lacking. Flavokawain A is a predominant
halcone, constituting up to 0.46% of kava extracts [21].
he  chemical structure of ﬂavokawain A is different from
avokawain B with an additional methoxy at position 4
9].  Recent studies have shown that ﬂavokawain A prefer-
bly  inhibited the growth of different cancer cell lines with
inimal  effect on the growth of liver cell lines (i.e. L-02
nd  HepG2) up to 100 M [8,22]. In addition, ﬂavokawain
 exhibited in vivo anti-tumor activity in a bladder cancer
enograft model and in the UPII-SV40T transgenic blad-
er  cancer mouse model [9,23]. Therefore, ﬂavokawain A
ppears  to be a promising chemopreventive agent in kava
xtracts.  To address concerns with respect to the poten-
ial  hepatotoxicity of ﬂavokawain A as a kava component,
e proposed to examine possible adverse effects of a high
ose  ﬂavokawain A (about 960 mg/kg body weight per
ay)  on liver function and homoeostasis. Drinking 1–4 g
f  kavalactones per day (about 60 mg/kg body weight) has
een  considered as regular consumption of traditional kava
24].  Based on a reported method [25] a human equiva-
ent dose of KRE used in the animal experiment here was
stimated to be about 78 mg/kg body weight human dose.
ompared to kava root extracts, mice fed with a high dose of
avokawain  A for three weeks did not affect food consump-
ion  and body weight, as well as exhibits no adverse effects
n  major organ function and homoeostasis. In addition, ﬂa-
okawain  A induces phase II enzyme activity in different
ouse tissues.rts 1 (2014) 2–11 3
2.  Materials and methods
2.1.  Reagents
Flavokawain A (FKA) was  purchased from sigma (St.
Louis, MO). Kava root extract (KRE) at a concentra-
tion of 150 mg/ml  kavalactones in 50% ethanol was
obtained from Gaia Herbs (Brevard, NC). Glutathione
S-Transferase (GST) Assay Kit was purchased from Cay-
man  Chemical Inc. (Ann Arbor, MI). 2,6-Dichlorophenol-
indophenol, -glucuronidase, and sulfase were obtained
from Sigma–Aldrich (St. Louis, MO). Human small intestinal
cell  line FHS was purchased from American Type Culture
Collection (ATCC) and maintained in Hybri-Care medium
(ATCC, Manassas, VA). The ATCC ensures authenticity of
these  human cell lines using short tandem repeat (STR)
analyses. All the other reagents or solvents used were com-
mercially available and of reagent grade.
2.2. Animal treatment with FKA or KRE for studying
toxicity
For toxicity study, male FVB/N mice at 6 weeks of age
were housed three per cage at 24 ± 2 ◦C and 50 ± 10% rela-
tive  humidity and subjected to a 12 h light/12 h dark cycle.
Mice  were randomly divided into four groups (6 mice per
group),  and Diets were commercially prepared by Dyets
(Bethlehem, PA). The use of male FVB/N here will facili-
tate  our planned work to test the chemoprevention efﬁcacy
of  dietary ﬂavokawain A on prostate cancer tumor growth
and  progression in the TRAMP mice with FVB/N genetic
background. Mice were fed either with control (AIN-76A)
or  AIN-76A diet supplemented with FKA [0.6% (w/w)] or
KRE  [0.6% (w/w)] for 3 weeks and water ad libitum. Body
weights were recorded weekly and diet consumption was
recorded  twice a week throughout the study. At the end
of  the experiment, mice were sacriﬁced by carbon dioxide
asphyxiation, and blood samples and organs were col-
lected  for further analyses. Use of mice and their care for
this  study was speciﬁcally approved by the University of
California,  Irvine Institutional Animal Care and Use Com-
mittee  (IACUC; protocol number 2007-2741).
2.3. Histological analysis
For  histological analysis tissue specimens were ﬁxed
for  24 h in buffered formaldehyde solution (3.7% in PBS)
at  room temperature, dehydrated by graded ethanol
and embedded in parafﬁn. Tissue sections (thickness
5 m)  were deparafﬁnized with xylene and stained with
eosin/hematoxylin (H&E). Digital images were captured
and  analyzed with a Nikon Eclipse TE2000-S microscope
(magniﬁcation, 100×).
2.4.  Biochemical serum analysis [26]Plasma samples were sent to IDEXX Laboratories (Irvine,
CA)  for preclinical services for analysis of plasma levels
of  alkaline phosphatase (ALP), alanine transaminase (ALT),
aspartate transaminase (AST), creatine phosphokinase
ogy Repo
diet  and to diet supplemented with 0.6% FKA (Ps < 0.05).
FKA  appears to slightly increase the daily food consumption
of  mice. Final body weights were 26.4 ± 2.190 g for con-
trol  mice, 20.4 ± 3.130 g for KRE-fed mice and 27.0 ± 1.732
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Fig. 1. The effect of dietary feeding of FKA or KRE on food consumption4 X. Li et al. / Toxicol
(CPK), lactic acid dehydrogenase (LDH), lipase, albumin,
creatinine, cholesterol, glucose, and lipemia index.
2.5. Cell proliferation and cytotoxicity assay
The cytotoxic effects of FKA on normal human small
intestinal epithelial cells (FHS) and murine bone marrow
cells  were tested using the cell counting kit-8 (Kumamoto,
Japan) following the kit instruction. FHS and murine bone
marrow  cells were exposed to 0.1% DMSO or different
concentrations of FKA for 72 h. Premixed water-soluble
tetrazolium salt (WST-1) was added into culture media and
measured  at 450 nm for densities of viable cells.
2.6.  Colony formation assay
Murine bone marrow cells were isolated from 6 to 8
weeks old Balb/c mice according to previously reported
methods [27]. After bone marrow cells were isolated, the
yield  and viability of cells were determined by Trypan blue
exclusion  method. A total number of 2 × 104 cells were
seeded in a 6-well plate containing Colony GelTM 1201
Mouse Base Medium (Reachbio), and then treated with FKA
and  Adriamycin at indicated concentrations for 2 weeks.
The  number of colonies was determined with an inverted
phase-contrast microscope at 40× magniﬁcation. A group
of  >10 cells was counted as a colony.
2.7. Animal treatment with FKA for phase II enzyme
studies
Seven-week-old mice were acclimatized for one week
before use in the present study and fed a Purina chow diet
and  water ad libitum. FKA at doses of 100 and 200 mg/kg
body  weight/day dissolving in 0.5% carboxymethylcellu-
lose sodium salt (CMC) was administered to mice by oral
gavage.  The control mice were orally given the same
amount of 0.5% CMC  solution. Each treatment group at each
time  point had ﬁve mice. These FKA treatments were given
once  in the morning daily and 24 h after 3, 7, 15 days mice
in  each group were sacriﬁced. The liver, lung, stomach,
bladder, kidney and prostate were removed and imme-
diately placed in ice-cold 0.1 M phosphate buffer, pH 7.4.
Tissue  were cleaned properly, minced and homogenized in
the  same buffer and 10,000 g supernatant fractions were
prepared to determine the activities of phase II enzymes:
Glutathione S-transferase (GST) and quinone reductase
(QR). GST activity was determined according to the kit
instruction using 1-chloro-2,4-dinitrobenzene (CDNB) as
substrate.  QR activity was determined as described by
Benson  et al. [28] using 2,6-dichlorophenol-indophenol
(DCP-IP) as electron acceptor.
2.8.  Statistics
Microsoft Excel software was used to compute mean
and  standard deviations of all quantitative data. Cell viabil-
ity  comparisons between treated and untreated (control)
cells  were accomplished using either analysis of variance
(ANOVA) or Student’s t-test. All statistical measures wererts 1 (2014) 2–11
two-sided, and P-values <0.05 were considered to be sta-
tistically  signiﬁcant.
3.  Results
3.1. Dietary feeding of FKA did not affect food
consumption and body weight of mice
To study potential toxic effects of orally administrated
FKA and KRE in vivo, mice were fed with AIN-76 A diet or
AIN-76  A supplemented with 0.6% (w/w) FKA or KRE daily
for  3 weeks. Fig. 1A shows that mice in the control group
consumed food about 2.981 ± 0.123 g daily, while those
in  the KRE and FKA groups ate food about 2.104 ± 0.211
and  3.134 ± 0.195 g daily, respectively. KRE signiﬁcantly
reduced the daily food consumption compared to controland body weight of mice. Mice (n = 6) were fed with AIN-76 A diet or AIN-
76  A supplemented with 0.6% (w/w) FKA or KRE daily for 3 weeks. Mouse
food consumption were recorded twice a week and body weight were
recorded weekly, (A) mean daily food intake of mice ± standard deviation
(SD) and (B) mean body weight of mice ± SD.
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Table 1
Serum analysis of control, KRE and FKA treated mice.
Parameter Control KRE FKA P-value
Creatinine (mg/dL) 0.20 ± 0.01 0.18 ± 0.08 0.18 ± 0.04 0.65#; 0.41$
Lipase (U/L) 71.75 ± 5.9 155.6 ± 183.7 83.2 ± 14.9 0.40#; 0.19$
CHOLESTEROL (mg/dL) 119.2 ± 52.6 156.2 ± 50.0 117.6 ± 37.9 0.24#; 0.96$
Creatine phosphokinase (IU/L) 289.4 ± 115.8 398.8 ± 152.2 248.6 ± 52.7 0.24#; 0.49$
LDH (IU/L) 345.25 ± 115.4 728.2 ± 455.2 899 ± 773.1 0.15#; 0.20$
Alkaline phosphatase (units/mg) 132.8 ± 64.3 128.6 ± 68.1 127.8 ± 39.4 0.91#; 0.90$
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The data shown are means ± SD of six independent mice.
# P values for KRE versus control.
$ P values for KRE versus control.
or FKA-fed mice (Fig. 1B). KRE fed mice have a signiﬁ-
antly less body weight gain over time compared to mice
ed  with control and FKA food (Ps < 0.05). However, there
as  no obvious difference between control and KRE or FKA
ed  mice in fecal excrements in terms of quantity, shape
nd  consistency. There were also no obvious clinical symp-
oms  (i.e. abnormal grooming behavior, abnormal shyness
r  lethargy, lameness, lethargy, anorexia) or deaths during
he  experimental period in all experimental mice.
.2. Effect of oral administration of FKA or KRE on
unction and homoeostasis of inner organs
To determine whether FKA or KRE intake affects func-
ion  and homeostasis of inner organs in mice fed with
ontrol or FKA diet, all major organs were inspected
or frank toxicity and weighed. In addition, systematic
ecropsy for gross and microscopic examination was car-
ied  out and blood was collected for analyzing indicating
arkers of organ function. Fig. 2A shows that dietary feed-
ng  of FKA for three weeks did not change ratios of organ to
ody  weight or organ weight [including heart, lung, spleen,
idney,  thymus, testis and genitourinary (GU, prostate,
eminal vesicles and bladder)], while KRE administration
igniﬁcantly increased the ratio of liver and testis to body
eight  and decreased ratios of thymus, spleen and GU to
ody  weight (Ps < 0.05, ANNOVA test).
Gross  examination demonstrated that FKA neither
ffected relative sizes of heart, lung, spleen, kidney, thy-
us,  colon and testis or caused any visible abnormality
e.g. hydronephrosis, change of organ color) compared to
ontrol  diet (Fig. 2B). Microscopical analysis revealed no
nﬂammation, ﬁbrosis, atrophy, alteration of parenchyma
nd mucosa or atypical epithelia in the tissue from these
rgans (Fig. 2C).
For  serum markers of toxicity, lipase activity in
he serum as a marker for the function of pancreas,
able 2
iver  relevant serum parameters of control, KRE and FKA treated mice.
Parameter Control KRE 
ALT (U/L) 106.4 ± 148.7 261.8 ± 3
AST (U/L) 226.0 ± 265.9 314.4 ± 2
Albumin (g/L) 3.02 ± 0.16 2.9 ± 0
Glucose (mg/dL) 269.2 ± 97.7 190.4 ± 4
he data shown are means ± SD of six independent mice.
# P values for KRE versus control.
$ P values for KRE versus control.creatine phosphokinase (CPK) as a marker for skeletal
muscle function and potential acute poisoning, serum
creatinine as a maker for kidney function, lactate dehy-
drogenase (LDH) as a marker for general toxicity and
cholesterol were assessed, Table 1 shows that there is
no  signiﬁcant difference between control and KRE or FKA
dietary  groups in the average levels of these markers for
organ  functions.
3.3.  Effect of dietary consumption of FKA or KRE on liver
function and homoeostasis
Although  experimental and epidemiological data have
demonstrated the potential of kava and its active compo-
nents as cancer chemopreventive agents, hepatotoxicity
remains to be a major concern for the use of kava or kava
components for cancer prevention. We  therefore evalu-
ated  the effect of dietary feeding of FKA or KRE on the
liver. Fig. 3A shows that neither absolute wet liver weight
nor  liver to body weight ratio differed between control
and FKA groups, whereas that dietary feeding of KRE
increased both wet  liver weight and liver to body weight
ratio.  Macroscopical examination of the livers revealed
no  signs of hepatotoxicity among all experimental groups
(Fig.  3B). Pathological analysis demonstrates a regular
structure of normal liver parenchyma with small por-
tal  tracts, regular reticulin network and low variation in
hepatocellular nuclei size in both control and FKA treat-
ment  groups. There is no identiﬁable inﬂammation or
steatosis (Fig. 3C). However, dietary feeding of 0.6% KRE
resulted in a signiﬁcant appearance of proliferating nod-
ules  consisting of closely packed hepatocytes in the liver
(Fig.  3D).Biochemical analyses of serum parameters indicative of
liver  damage and hepatic synthesis capacity shows that
there  are no signiﬁcant difference in the average serum lev-
els  of ALT, AST and alkaline phosphatase (ALP), as well as
FKA P-value
46.4 164.6 ± 159.0 0.38#; 0.57$
96.9 262.8 ± 225.6 0.63#; 0.82$
.41 3.1 ± 0.21 0.35#; 0.70$
4.9 243.4 ± 45.7 0.14#; 0.60$
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Fig. 2. Macroscopical and microscopical examination of inner organs after FKA or KRE feeding. Mice were treated as described above. (A) Mean percentage
of  organ to body weight ± SD, (B) representative photographs of lung, heart, thymus, spleen, kidney (from left to right) and (C) H&E staining of different
organ  tissues, magniﬁcation 100×.
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eight-ratio of FKA and KRE treated and control mice after 3 weeks (me
nalysis  of sections of hepatic tissue (H&E staining; bars represent 500 m
lbumin, cholesterol and glucose among mice of KRE, FKA
nd  control treatment groups (Table 2).
.4. The toxic effect of FKA or KRE on human normal
mall intestinal epithelial cells and mouse bone marrow
ells
Fig.  4A shows that both FKA and KRE at a dose of up to
5  g/ml have very low or minimal toxicity to fast-growing
uman normal small intestinal epithelial cells. This dose
f  FKA or KRE has been shown to completely inhibit the
rowth  of cancer cell lines.
In  addition, the potential toxicity of FKA or KRE to
one marrow was investigated by using mouse bone mar-
ow  cells. No signiﬁcant growth inhibitory effects on bone
arrow  cells were observed following FKA and KRE treat-
ents  for 72 h (Fig. 4B). Bone marrow cell colony formation
evealed that there was also no signiﬁcant difference in the
umber  of colonies after FKA and KRE treatments (Fig. 5A
nd  B, Ps > 0.05). However, a signiﬁcant inhibition of colonye fed as described above. (A) Absolute liver weight and (B) liver-to-body-
). (C) Representative photographs of the whole liver and (D) histological
 upper and 100 m in the lower row).
formation  was noted with Adriamycin treatment at all con-
centrations (Fig. 5A and B, Ps < 0.05–0.01).
3.5.  Enhancement of phase II enzyme activities by FKA
The  enhancement of phase II enzyme activities has
been thought to be an effective mechanism for pre-
vention of cancer by chemopreventive agents [28]. FKA
contains an electrophilic ,-unsaturated ketone, which
might react with intracellular GSH to form conjugates and
then  transcriptionally induce phase II enzyme activities for
protection  against carcinogenesis [29]. To investigate this
possibility, studies were also performed to assess the effect
of  orally administered FKA on both GST and QR enzyme
activities. As shown in Tables 3 and 4, oral administration
of FKA resulted in a different degree of increase in both
GST  and QR activities in all the tissues examined. In the
case  of QR activity, compared with vehicle-treated con-
trols,  treatment with 100 and 200 mg/kg doses of FKA for
3,  7 and 15 days resulted in 11.1–248% and 12.5–258%
8 X. Li et al. / Toxicology Reports 1 (2014) 2–11
Table 3
Oral  administration of FKA to mice induces QR activities in different tissues.
FKA (mg/kg) QR (nmol DCP-IP reduced/min/mg protein)
0 3 7 15 (days of administration)
Liver 0  (control) 2648.06 ± 183.35 2436.80 ± 1398.10 2741.66 ± 137.60 2765.72 ± 2093.37
100  4101.02 ± 1105.19 3527.77 ± 517.85* 9634.45 ± 5313.81*
200 8504.29 ± 3470.56* 4068.79 ± 232.22* 7068.51 ± 3294.60*
Bladder 0  3449.71 ± 209.77 3273.61 ± 1415.96* 3393.723 ± 443.62 3681.79 ± 100.181
100  11737.22 ± 4084.48* 3467.52 ± 688.35 5170.27 ± 739.32*
200 10511.25 ± 1472.25* 3770.84 ± 1072.36 3089.84 ± 768.84
Prostate 0  2802.91 ± 64.67 2756.19 ± 1587.58 2876.72 ± 2198.77 2775.82 ± 1878.86
100  2310.67 ± 226.59 5523.26 ± 969.70* 6807.09 ± 1674.26*
200 2337.18 ± 1150.77 5119.12 ± 4551.13 6411.29 ± 1356.39*
Lung 0  4870.35 ± 39.78 4851.78 ± 527.02 4916.02 ± 2880.84 4843.25 ± 1181.73
100  3857.17 ± 1549.93 4524.02 ± 5647.48 3473.61 ± 1628.91
200  4339.79 ± 88.12 11079.75 ± 1966.66* 8950.10 ± 2933.21
Stomach 0  60479.048 ± 3081.32 64021.47 ± 5996.13 59000.77 ± 14874.92 58416.41 ± 12850.78
100  57294.48 ± 11656.99 50044.99 ± 15353.51 91235.17 ± 20875.47*
200 74057.26 ± 30492.55 59889.06 ± 9694.78 69008.18 ± 11494.82
Small intestine 0  40637.76 ± 1523.47 41885.29 ± 4398.57 38927.15 ± 2909.39 41100.84 ± 18778.52
100  74065.44 ± 8922.01 43262.27 ± 1309.49* 54448.36 ± 9452.83*
68.51 ± *200 605
The data shown are means ± SD of ﬁve independent mice.
* Statistically signiﬁcant versus control group, P < 0.05 (t-test).
increases (Ps < 0.05, Student’s t-test) in enzyme activity.
The observed increase in QR activity was more pronounced
in  liver, prostate and bladder and accounted for the 110,
140%  and 258% increases (P < 0.001, Student’s t-test) over
control  for 200 mg/kg dose, respectively (Table 3). For
GST  activity, compared with vehicle-treated controls, the
increases  in GST activity were also signiﬁcant in liver and
bladder  at the 100 mg/kg or 200 mg/kg dose of FKA after
3  days treatment (Table 4, Student’s t-test, P < 0.01). In
general, the increases in GST activity in liver, bladder and
Table 4
Oral  administration of FKA to mice induces GST activities in different tissues.
FKA (mg/kg) GST (nmol/min/mg)
0 3 
Liver 0  729.47 ± 33.87 740.10 ±
100  1191.81 ±
200 1015.37 ±
Bladder 0  450.71 ± 18.20 444.29 ±
100  746.65 ±
200  759.97 ±
Prostate 0  208.93 ± 4.62 205.41 ±
100  233.77 ±
200  239.19 ±
Lung 0  229.89 ± 10.54 217.91 ±
100  188.04 ±
200  233.59 ±
Stomach 0  169.84 ± 6.27 163.94 ±
100  194.46 ±
200 232.99 ±
Small intestine 0  242.88 ± 16.18 224.68 ±
100  273.20 ±
200 296.34 ±
The data shown are means ± SD of ﬁve independent mice.
* Statistically signiﬁcant versus control group, P < 0.05 (t-test). 2085.84 43810.33 ± 472.22 47506.90 ± 10479.29
prostate  were not as profound as those in QR activity
(Tables 3 and 4). There is no obvious dose- and time-
dependent effect of FKA in induction of phase II enzyme
activities. However, oral administration of FKA resulted
in  less pronounced increases in GST and QR activities in
lung  tissues than those in liver, prostate and bladder tis-
sues.  The maximum increase in QR activity by FKA in
lung  tissue is 125% versus 248% in liver and 258% in
bladder (ANOVA test, P < 0.05). The maximum increase
in  GST activity by FKA in lung tissue is 13% versus 61%
7 15(days of administration)
 112.58 691.56 ± 86.74 756.76 ± 83.00
 235.47* 711.04 ± 25.47 1203.04 ± 243.90*
 108.39* 700.25 ± 62.66 1013.56 ± 107.02*
 44.89 471.15 ± 108.47 436.58 ± 55.70
 134.09* 520.07 ± 99.02 488.46 ± 63.37
 67.51* 564.10 ± 76.31 434.44 ± 48.89
 85.90 207.2352 ± 11.59 214.17 ± 23.70
 86.73 198.486 ± 15.16 230.93 ± 41.64
 90.09 201.506 ± 23.59 220.78 ± 19.94
 11.30 237.75 ± 44.33 234.02 ± 101.90
 43.10 228.28 ± 35.06 230.62 ± 20.06
 28.391 275.74 ± 10.79 265.59 ± 56.67*
 27.03 176.44 ± 64.28 169.14 ± 13.58
 13.51 211.20 ± 31.71 223.55 ± 15.44*
 46.97* 214.10 ± 14.58 220.38 ± 18.62*
 39.81 248.30 ± 34.72 255.67 ± 42.49
 19.50* 393.39 ± 105.97* 307.94 ± 17.81*
 22.11* 394.84 ± 50.59* 274.42 ± 39.89
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Fig. 4. Analysis of potential toxic effect of FKA, KRE and Adriamycin (ADM)
on normal small intestinal epithelial cell (FHS) and mouse bone marrow
cells. FHS and mouse bone marrow Cells were treated with 0.1% DMSO,
FKA, KRE, or ADM at indicated doses for 72 h. After these treatments, cell
densities were measured by MTT  assay. Each point is the mean percentage
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tf cell density values relative to vehicle control; bars, SD. (A) FKA and
RE have minimal effect on the growth of FHS cells up to 25 g/ml. (B)
ompared with ADM, FKA and KRE showed signiﬁcantly less bone marrow
nhibition effect.
n liver tissues and 71% in bladder tissues (ANOVA test,
 < 0.05).
. Discussion
Traditional kava preparation has been considered to be
afe  for daily use in the South Paciﬁc Island Nations for
housands of years until there had been several reports of
uspected  commercial kava extracts-induced acute liver
oxicity  in Western countries, including Europe and the
SA  between 1990 and 2002 [30]. Therefore, the poten-
ial  hepatotoxicity of KRE has recently been examined by
everal  groups in rats or mice, as well as in human [31–39].
owever, the results from these studies are conﬂicting and
ava  hepatotoxicity remains a matter of debate. Most of
hese  studies [34,35,37–39] have shown that KRE failed
o  result in toxicity and increases in serum markers (i.e.
LT  and AST) of hepatotoxicity in rat and mice. In addition,
linical studies showed that compared with abstainers and
on-drinkers in Australian aboriginal and Tongan popula-
ions,  recent kava drinkers had signiﬁcantly elevated serumrts 1 (2014) 2–11 9
levels  of the cholestatic enzymes -glutamyl transferase
(GGT) and alkaline phosphatase (ALP) without increased
ALT or AST levels [31–33]. These results suggested biliary
inﬂammation rather than hepatocellular damage in kava
drinkers.  In a National Toxicology Program study, rats and
mice  that were fed with 0.125–2 g commercial kava root
extracts/kg body weight by gavage for two  weeks, thir-
teen  weeks or two years exhibited dose- and time-related
increases in liver weights and incidences of hepatocellular
hypertrophy [36]. The manifestation of this hepatotoxic-
ity is also not consistent with the reported hepatotoxicity
in human, which is of idiosyncratic, unpredictable, and
dose-independent nature and was thought to be due to
aberrant drug metabolism in a small portion of kava users
in  the Western countries [18,37,40]. Histologically, the
kava  hepatotoxicity in human is more related to hepatocel-
lular liver disease, including necrosis, hepatitis, cirrhosis,
and  liver failure, while the kava hepatotoxicity in rodents
was  characterized by increased incidences of hepatocellu-
lar hypertrophy, which is often associated with an adaptive
response to enzyme induction by xenobiotics [36,40,41].
Our study showed that commercial KRE increased liver
weight and resulted in a signiﬁcant appearance of prolif-
erating nodules, further suggesting that the commercial
KRE act through enzyme induction to induce liver lesions in
mice.  However, our results still cannot explain the potential
toxicity of KRE in human.
The  complex kava extracts contain many bioactive
ingredients. Currently, there is no sufﬁcient evidence for
a  causative role of any individual kava component, such
as  pipermethystine and ﬂavokawain B, in kava hepato-
toxicity. FKA is the principal chalcone in the Kava plant
[21].  In general, chalcones are well tolerant in many ani-
mal  experiments and considered non-toxic. Citrus fruits
and  apples are rich dietary sources of chalcones [42]. The
maximum tolerant doses of some chalcones in rodents
were shown to be more than 1–3 g/kg body weight [43].
Previous studies from us and other groups have demon-
strated that FKA at concentrations signiﬁcantly inhibits the
growth  of many types of cancer cell lines with minimal
effect on the growth of normal cells derived from different
types of tissues, including breast, liver, prostate, ﬁbroblast,
intestine, and bone marrows (Fig. 4 and data not shown).
We  have recently shown that 0.6% FKA feeding of UPII-
SV40T transgenic mice for 290 days did not result in any
noticeable toxicity. The maximum detected FKA concen-
tration in plasma of these mice is about 1.8 M.  However,
Li  et al. [22] reported that the IC50s of FKA to human nor-
mal  liver cells L-02 and human hepatoma cells HepG2 cells
are  more than 100 M.  Therefore, it is unlikely that the
in  vitro concentrations of FKA for hepatocellular toxicity
can  be applied to the in vivo situations. In this study, mice
that  were fed with standard diet supplemented with 0.6%
FKA  to achieve a daily dose of about 960 mg  FKA/kg body
for  3 weeks exhibited neither absolute wet liver weight
increase nor liver to body weight ratio gain, as well as
no  changes in food and water consumption. Pathologi-
cal analysis demonstrates a regular structure of normal
liver parenchyma with small portal tracts; regular retic-
ulin  network and low variation in hepatocellular nuclei
size  without any identiﬁable inﬂammation or steatosis.
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) on colo
ell colonFig. 5. Analysis of potential toxic effect of FKA, KRE and Adriamycin (ADM
tography,  taken at 14 days after treatment of mouse bone marrow stem c
bone  marrow stem cells for 14 days; bars, SD.
The examination of liver function and homeostasis serum
biomarkers (i.e. ALT, AST, albumin, glucose and others) in
FKA  fed mice also revealed no liver damage and no changes
in  hepatic synthesis capacity. Taken together, these results
indicated a satisfactory/excellent safety proﬁle of FKA.
Phase  II enzymes, including GST and QR, play a critical
role in detoxiﬁcation of activated carcinogenic interme-
diates [44]. Consequently, induction of phase II enzyme
activities by chemopreventive agents has become a major
mechanism for alteration of carcinogen metabolism and
cancer  prevention. In this study, increases in phase II
enzyme activity induced by FKA were clearly evident in
the  mouse liver, prostate and bladder. This result may  form
the  basis for more detailed studies in the future to evaluate
the  cancer preventive and interventive effects of FKA, the
predominant chalcone in the kava plant, in experimental
models of carcinogenesis representing liver, prostate and
bladder  sites.
In  conclusion, oral administration of FKA to mice in a
dose  as high as 960 mg/kg body per day did not cause anyny formation of mouse bone marrow cells. (A) Representative micropho-
ies. (B) The mean number of colony formation after treatment of mouse
toxicity  or adverse effects. In particular, the potential hep-
atotoxicity of FKA could be ruled out. FKA signiﬁcantly
induces activity of phase II enzymes, including GST and
QR,  in the mouse liver, prostate and bladder. FKA prefer-
ably  inhibits the growth of cancer cells with no or minimal
effects on the growth of several types of normal cells.
Therefore, FKA is an excellent candidate for cancer chemo-
prevention studies. Further studies are needed to assess
the  cancer preventive and anticarcinogenic effects of ﬂa-
vokawain A in different cancer models for prostate and
bladder cancer prevention.
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